Roche has bought Inflazome for €380 million ($451 million) upfront to gain control of treatments for inflammatory diseases. The deal gives Roche full rights to a pipeline of oral NLRP3 inhibitors led by two clinical-phase drugs Inflazome is developing as treatments for Parkinson’s and other diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,